Status:
COMPLETED
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating b...
Eligibility Criteria
Inclusion
- Histologically confirmed adenocarcinoma or prostate
- Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL)
- Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2
- Patient who signed informed consent
Exclusion
- Severe disorders of coagulation
- Major skin lesion on iliac crests
- Allergies in local anesthetics
- Psychological instability or psychiatric histories
- Uncertain follow-up and distant residence
- History of another invasive cancer and hematologic disease
- Patient deprived of their freedom by court or administrative order
- Revocation of consent
Key Trial Info
Start Date :
September 8 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2017
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02282644
Start Date
September 8 2014
End Date
August 25 2017
Last Update
February 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot - service d'urologie
Lyon, France, 69003